Monosodium urate crystal deposition associated with the progress of radiographic grade at the sacroiliac joint in axial SpA: a dual-energy CT study

Junqing Zhu1, Aiwu Li2, Ertao Jia2, Yi Zhou3, Juan Xu2, Shixian Chen2, Yinger Huang2, Xiang Xiao4 and Juan Li2,1*

Abstract
Background: Previous studies have revealed that ankylosing spondylitis (AS), as the progenitor of axial spondyloarthritis (AxSpA), has been characterized by the insidiously progressive nature of sacroiliitis and spondylitis. Dual-energy computed tomography (DECT) has recently been used to analyse the deposition of monosodium urate (MSU) crystals with higher sensitivity and specificity. However, it remains unclear whether the existence of the MSU crystal deposition detected by DECT at the sacroiliac joint in patients with AxSpA also is associated with the existing structural damage. Here, we performed this study to show the DECT MSU crystal deposits in AxSpA patients without coexisting gout and to ascertain the relationship between the MSU crystal deposition and the structural joint damage of sacroiliac joints.

Methods: One hundred and eighty-six AxSpA patients without coexisting gout were recruited. The plain radiographs of the sacroiliac joint were obtained, along with the DECT scans at the pelvis and the clinical variables. All statistics based on the left or right sacroiliac joint damage grading (0–4) were calculated independently. Bivariate analysis and ordinal logistic regression was performed between the clinical features and radiographic grades at the sacroiliac joint.

Results: At the pelvis, large quantities of MSU crystal deposition were found in patients with AxSpA. The average MSU crystal volume at the left sacroiliac joint, the right sacroiliac joint, and the pelvis were 0.902 ± 1.345, 1.074 ± 1.878, and 5.272 ± 9.044 cm³, values which were correlated with serum uric acid concentrations (r = 0.727, 0.740, 0.896; p < 0.001). In bivariate analysis, wide clinical variables were associated with the changes in sacroiliac joint damage. Further, the AxSpA duration, BASFI score, and the volume of MSU crystal at both sides of sacroiliac joint were associated with the progress of radiographic grade at the sacroiliac joints in the ordinal logistic models (left AOR = 1.180, 3.800, 1.920; right AOR = 1.190, 3.034, 1.418; p < 0.01).

Conclusions: Large quantities of MSU crystal deposition detected by DECT were found at the pelvis in AxSpA patients without coexisting gout. In addition to AxSpA duration and BASFI score, the MSU crystal deposition at the sacroiliac joint is associated with the progress of radiographic grade at sacroiliac joints in those patients.

Keywords: Axial Spondyloarthritis (AxSpA), Ankylosing spondylitis (AS), Dual-energy computed tomography (DECT), Monosodium urate (MSU) crystal, Sacroiliac joint
Background

The term spondyloarthritis (SpA) encompasses a group of diseases including axial SpA (AxSpA) and peripheral SpA, classifications which have been proposed by the Assessment of SpondyloArthritis International Society (ASAS) [1, 2]. It is estimated that SpA, with an incidence between 0.5 and 10.6 per 100,000 people per year, affects approximately 0.4–1.9% of the population across the globe [3]. In addition to what is now known as nonradiographic AxSpA (nr-AxSpA), ankylosing spondylitis (AS) has been characterized by the insidiously progressive nature of sacroiliitis and spondylitis, which leads to a significant reduction in quality of life and an increased mortality rate [4]. Although the aetiology and pathogenesis of AxSpA has not yet been fully elucidated, the current view is that it involves both inflammatory erosive osteopenia and unusual bony overgrowth [5, 6]. Precisely because the primal mechanism in autoimmune disorders is the loss of tolerance to self-proteins by environment-gene interactions, the coexistence of different rheumatic diseases is common. For example, AS grouped under the term AxSpA occurs in patients with rheumatoid arthritis (RA) [7, 8], gouty arthritis [9], multiple sclerosis [10, 11], and systemic lupus erythematosus [12].

There are few epidemiological publications regarding the coexistence of AxSpA and gout, but the study has revealed that AS concurrent with gout is more common than previously believed [9]. Although AxSpA and gout are two distinct rheumatic diseases, they share a few clinical characteristics, including inflammatory joint pain and excellent response to non-steroidal anti-inflammatory drugs (NSAIDs). AxSpA usually leads to structural damage and functional limitation, exemplified in patients with AS [13]. At the same time, structural joint damage is also frequently observed in patients with advanced gout as a result of monosodium urate (MSU) crystal deposition [14–16]. Therefore, in patients with coexisting AS and gout, it is hard to discriminate whether the inflammatory joint pain and structural joint damage are due to AS disease activity, the MSU crystal deposition, or both.

Dual-energy computed tomography (DECT) has been used to analyse the deposition of MSU crystal with high sensitivity (100%) and specificity (89%) [17]. The sensitivity and specificity of DECT for gout were only 0.87 and 0.84 [18], because the deposition of MSU crystal is a necessary but not a sufficient condition. Besides, DECT MSU crystal deposition was observed in both multiple joints and soft tissues in patients with asymptomatic hyperuricaemia, and was associated with increasingly severe coronary calcification [19, 20]. In addition, our study found a large quantity of MSU crystal deposition with DECT in AxSpA patients without coexisting gout, according to the 1977 American Rheumatism Association classification criteria [21]. However, whether the existence of MSU crystal deposition in those patients has contributed to the structural joint damage is still unclear.

The purpose of our study was to show the DECT MSU crystal deposits at the pelvis in AxSpA patients without coexisting gout, and further to analyse whether the MSU crystal deposition at the sacroiliac joint is associated with the structural joint damage of the sacroiliac joint in those patients.

Methods

One hundred and eighty-six patients with AxSpA were recruited from rheumatology clinics at Nanfang Hospital in China during the period of October 2012 to July 2015. All participants had AxSpA described by the ASAS classification criteria [1, 2] and had not been diagnosed with gout, according to the 1977 American Rheumatism Association classification criteria [21].

The plain radiographs of the sacroiliac joint, a DECT scan of pelvis, and the clinical variables were obtained at a follow-up appointment. In brief, each sacroiliac joint on a plain radiograph was graded on a scale of 0–4 according to the modified New York criteria [22]. DECT scans were performed on a dual-source X-ray tube 128 detector row scanner (Somatom Definition Flash, Siemens Healthcare, Erlangen, Germany). All scans were performed using the same image protocol: acquisition at 128 mm × 0.6 mm and pitch of 0.7. The two X-ray tubes are operated simultaneously at 80 kV and 140 kV. The image reconstructions were done using proprietary software (Siemens Multimodality Workplace, Software version MMWP Syngo CT 2010A, Siemens Healthcare, Erlangen, Germany), with a 512 × 512 matrix, to 0.75-mm slices, with a 0.5-mm increment. The parameter ratio for urate was set at 1.28. Two readers, blinded to the clinical variables and plain radiographic scores, evaluated the DECT scans for the presence and volumes of MSU crystal, independently. MSU crystal was considered present at each site only if reported by both readers and the average volume of MSU crystal was calculated [23].

The clinical variables, including age, gender, AxSpA disease duration, HLA-B27 positivity, erythrocyte sedimentation rate (ESR, mm/h), C-reactive protein (CRP, mg/l), total back pain (10-cm visual analogue scale,VAS), patient’s global assessment (PGA) of disease activity (10-cm VAS), pain and swelling of peripheral arthritis (10-cm VAS), duration of morning stiffness (10-cm VAS), use of non-steroidal anti-inflammatory drugs (NSAIDs), use of disease-modifying anti-rheumatic drugs (DMARDs), use of biologic DMARDs, serum uric acid (μmol/L), MSU crystal positivity, and volume of MSU crystal (cm³) were all assessed. In addition, the Ankylosing Spondylitis Disease Activity Score (ASDAS) [24] and the grading for disease activity [25] were
calculated as previous study. The Bath Ankylosing Spondylitis Functional Index (BASFI) scores were calculated according to the average scores of ten questions [26].

All statistics based on the left or right sacroiliac joint damage grading were calculated independently with IBM SPSS (Version 20.0, IBM Corp., Armonk, NY, USA). Measurement data were presented as mean ± standard deviation (mean ± SD) or with a 95% confidence interval (CI), while count data were presented as numbers (n). One-way analysis of variance (ANOVA) was used to evaluate the statistical differences among groups. The non-normal distribution measurement data were tested with the Kruskal-Wallis rank-sum test. To count data, Pearson's chi-square (\(x^2\)) and Fisher's exact test were used for the comparison. Interobserver reproducibility for the volume of MSU crystals by two readers was assessed by the intraclass correlation coefficient (ICC) and limits of agreement by Bland-Altman analysis [27]. The ICC values, 95%CI, and the p values were reported. Spearman's correlation analysis was performed to evaluate the association between serum uric acid and the average volume of MSU crystal. Spearman's rank correlation coefficient (\(r\)) and \(p\) values were reported. Bivariate analysis was performed between the clinical features and radiographic grades. The odds ratios (OR) and its 95%CI were reported. In addition, the ordinal logistic regression was used to identify the effect of each potential factor adjusted for others. Variables with \(p<0.05\) in bivariate analysis were included in the ordinal logistic models. The adjusted odds ratios (AOR) 95%CI were reported. A test of parallel lines was also performed to evaluate the appropriateness of the ordinal logistic model. A \(p<0.05\) was considered statistically significant. All \(p\) values were two-tailed.

**Results**

**Clinical characteristics of the patients with AxSpA**

The 186 patients' clinical features are shown in Table 1. Patients were predominantly young males and were HLA-B27 positive. Mean disease duration was 4.3 years, mean ESR was 25.1 mm/h, and mean serum uric acid was 362.7 μmol/L. The median ASDAS scores and BASFI scores were 2.7 ± 1.1 and 4.3 ± 1.1. Seventeen and fifty-seven patients had never used NSAIDs or biologic DMARDs. Seventeen patients had used DMARDs for less than 3 months. Large quantities of MSU crystal deposition detected by DECT were found at the pelvis in AxSpA patients without coexisting gout. The positive rates of MSU crystal at the sacroiliac joint, hip joint, and pubic symphysis were 111 (29.8%), 75 (40.3%), and 63 (33.9%). The average volumes of MSU crystal at the sacroiliac joint and pelvis were 0.29 ± 0.99 and 4.37 ± 8.46 cm³.

The statistically significant results were found among the radiographic grade group at the left or right sacroiliac joints for disease duration, ESR, CRP, total back pain, PGA of disease activity, duration of morning stiffness, ASDAS scores, BASFI scores, use of NSAIDs/DMARDs/biologic DMARDs, as well as the presence and volume of MSU crystal on the left and right sacroiliac joints (\(p<0.05\)) (Table 1).

**Reproducibility of DECT MSU crystal volume measurement and correlation between the average MSU crystal volume and serum uric acid**

Of the patients who showed the presence of MSU crystal deposition, 57 showed deposition at the left sacroiliac joint, 54 at the right sacroiliac joint, and 154 at the pelvis. The interobserver reproducibility analysis is shown in Table 2. ICCs for MSU crystal volume measurements at the sacroiliac joint and pelvis were all greater than 0.99 (\(p<0.001\)). Bland-Altman plots illustrating the interobserver limits of agreement for MSU crystal volume measurements are shown in Fig. 1. The average MSU crystal volume measurements at the left sacroiliac joint, the right sacroiliac joint, and the pelvis were 0.902 ± 1.345, 1.074 ± 1.878, and 5.272 ± 9.044 cm³. For further analysis, the serum uric acid concentration was correlated with the volumes of MSU crystal at the left sacroiliac joint (\(r=0.727, p<0.001\)), the right sacroiliac joint (\(r=0.740, p<0.001\)), and the pelvis (\(r=0.896, p<0.001\)) (Table 2).

**Comparison of MSU crystal deposition and serum uric acid in patients grouped by ASDAS scores**

According to the ASDAS scores, all patients were divided into four groups (Table 3). The presence of MSU crystal deposition at the left and right sacroiliac joints showed statistical differences among groups (\(x^2=11.451, 43.684; p=0.010, <0.001\)). However, there was no statistical difference among groups at the hip joint and pubic symphysis for the presence of MSU crystal deposition (\(x^2=0.676, 0.549; p=0.879, 0.908\)). Statistical differences were found in regards to the volumes of MSU crystal at the left sacroiliac joint (\(Z=9.198, p=0.027\)), the right sacroiliac joint (\(Z=34.607, p<0.001\)), and the pelvis (\(Z=10.517, p=0.015\)). In addition the ANOVA tests revealed that the serum uric acid concentration was statistically different among groups (\(F=6.322, p<0.001\)).

**Unadjusted associations of clinical features with the grade of sacroiliac joint damage**

In bivariate analysis (Table 4), wide clinical variables were associated with the changes in sacroiliac joint damage based on the radiographic grade at the left sacroiliac joint. The OR scores were 1.189 (95%CI 1.103–1.283) for disease duration, 1.024 (95%CI 1.011–1.037) for ESR,
| Table 1 Characteristics of the patients with AxSpA included in the study |
|-------------------------------------------------|
| **Total** | **Based on the left sacroiliac joint damage** | **Based on the right sacroiliac joint damage** | **p value** |
| Number of cases (n) | 186 | 4 | 0.138 | 4 |
| Age (years) | 26.4 ± 8.7 | 23.9 ± 10.7 | 0.13 | 23.7 ± 9.4 |
| Male/female (n) | 143/43 | 3/1 | <0.001 | 3/1 |
| AxSpA duration (years) | 4.3 ± 4.0 | 0.8 ± 0.3 | <0.001 | 0.8 ± 0.3 |
| HLA-B27 (+/-) (n) | 164/22 | 3/1 | <0.001 | 3/1 |
| ESR (mm/h) | 25.1 ± 22.1 | 9.5 ± 10.6 | 0.002 | 9.5 ± 10.6 |
| CRP (mg/l) | 14.3 ± 17.5 | 3.1 ± 2.4 | <0.001 | 3.1 ± 2.4 |
| Total back pain # | 4.9 ± 2.8 | 1.3 ± 0.5 | <0.001 | 1.3 ± 0.5 |
| PGA of disease activity # | 5.6 ± 3.0 | 2.5 ± 1.9 | <0.001 | 2.5 ± 1.9 |
| Duration of morning stiffness # | 5.4 ± 2.8 | 2.8 ± 1.0 | <0.001 | 2.8 ± 1.0 |
| ASDAS (scores) | 2.7 ± 1.1 | 1.4 ± 0.4 | <0.001 | 1.4 ± 0.4 |
| BASFI (scores) | 4.3 ± 1.1 | 2.5 ± 0.9 | <0.001 | 2.5 ± 0.9 |
| Use of NSAIDs (ever/never) (n) | 169/17 | 0/4 | <0.001 | 0/4 |
| Use of DMARDs (ever/never) (n) | 169/17 | 3/2 | <0.001 | 3/2 |
| Serum uric acid (μmol/L) | 362.7 ± 107.9 | 284.0 ± 95.3 | <0.001 | 284.0 ± 95.3 |
| MU crystalization (+/-) (n) | 111 | 0/4 | <0.001 | 0/4 |
| MU crystalization (cm^3) | 0.29 | 0.09 | 0.002 | 0.09 |
| Values are given as the numbers or the mean ± standard deviation (Mean±SD); AxSpA axial spondyloarthritis, n numbers, +/- positive/negative, ESR erythrocyte sedimentation rate, CRP C-reactive protein, PGA patient’s global assessment, ASDAS Ankylosing Spondylitis Disease Activity Score, BASFI Bath Ankylosing Spondylitis Functional Index, NSAIDs non-steroidal anti-inflammatory drugs, DMARDs disease-modifying anti-rheumatic drugs, MU monosodium urate, NA not available |
| *All assessed on a visual analogue scale (0–10 cm) |
| *The sum of the data from the left and right sacroiliac joint |

Zhu et al. Arthritis Research & Therapy (2017) 19:83
Adjusted associations of clinical features with the grade of sacroiliac joint damage

In the ordinal logistic models, variables with $p < 0.05$ in bivariate analysis were included (complex model 1 and 3, Table 5). For the radiographic grade at the left sacroiliac joint, the adjusted factors were AxSpA duration, total back pain, BASFI score, and the volume of MSU crystal at the left sacroiliac joint (AOR = 1.187, 1.428, 3.837, 2.018; 95% CI 1.089–1.294, 1.040–1.962, 2.263–6.506, 1.144–3.560; $p < 0.001$, $p = 0.028$, $p < 0.001$, $p = 0.015$). The same adjusted factors were obtained at the right sacroiliac joint, except the variable of total back pain. The AOR values were 1.188, 3.092, and 1.387 (95% CI 1.090–1.295, 1.896–5.044, 1.022–1.882; $p < 0.001$, $p < 0.001$, $p = 0.036$) for the variables of AxSpA duration, BASFI score, and the volume of MSU crystal at the right sacroiliac joint.

In addition, the simplified models (simplified model 2 and 4, Table 5), which excluded the repeated variables of the ASDAS score and presence of MSU crystal deposition, were also performed. The AxSpA duration, BASFI score, and the volume of MSU crystal at the left sacroiliac joint (AOR = 1.180, 3.800, 1.920; 95% CI 1.086–1.283, 2.250–6.417, 1.209–3.049; $p < 0.001$, $p < 0.001$, $p = 0.006$) were associated with the progress of radiographic grade at the left sacroiliac joint after being adjusted for other potential factors, while the duration of morning stiffness was a protective factor (AOR = 0.682, 95% CI 0.494–0.942, $p = 0.020$). In the simplified ordinal logistic model at the right sacroiliac joint, AxSpA duration, BASFI score, and the volume of MSU crystal at the right sacroiliac joint were the main factors when others factors were adjusted (AOR = 1.190, 3.034, 1.418; 95% CI 1.096–1.293, 1.870–4.922, 1.075–1.870; $p < 0.001$, $p < 0.001$, $p = 0.014$).

The test for parallel lines was not significant in the complex model 1, simplified model 2, and simplified model 4 ($x^2 = 34.904$, 13.028, 40.234; $p = 0.773$, 1.000, 0.288), which suggests that the models are appropriate. However, the parameter estimation is less stable for complex model 2 ($x^2 = 59.877$, $p = 0.036$).

The MSU crystal at the sacroiliac joint with radiographic sacroiliac joint damage in four separate patients with AxSpA

Examples of corresponding radiographic and DECT images of affected sacroiliac joints are shown in Fig. 2. Four male patients (patient 1–4), aged 36, 44, 23, and 27 years old, had serum uric acid levels of 407 µmol/L,

---

**Table 2** The interreader reproducibility analysis of MSU crystal volume and its correlation with the serum uric acid

| Joint                  | Reader       | Volume of MSU crystallization (cm³) | Intraclass correlation coefficient | Correlation with serum uric acid* |
|------------------------|--------------|-----------------------------------|-----------------------------------|----------------------------------|
|                        | Mean ± SD    | 95% CI                            | ICC 95% CI                        | $r$ |
| Left sacroiliac joint  | Reader 1     | 0.900 ± 1.351                     | 0.541–1.258                       | 0.099 0.998–0.999 0.001 NA NA |
|                        | Reader 2     | 0.904 ± 1.340                     | 0.549–1.260                       | NA NA NA 0.727 <0.001 |
| Pelvis                 | Reader 1     | 1.078 ± 1.878                     | 0.578–1.619                       | 1.000 0.999–1.000 0.001 NA NA |
|                        | Reader 2     | 1.071 ± 1.878                     | 0.5700–1.612                      | NA NA NA 0.740 <0.001 |
| Pelvis (n = 154)       | Reader 1     | 5.237 ± 9.842                     | 3.813–6.660                       | 0.999 0.999–0.999 0.001 NA NA |
| Pelvis                 | Reader 2     | 5.307 ± 9.150                     | 3.850–6.764                       | NA NA NA 0.896 <0.001 |
| Pelvis                 | Average      | 5.272 ± 9.044                     | 3.832–6.712                       | NA NA NA 0.896 <0.001 |

Values are given as the mean ± standard deviation (mean ± SD). MSU monosodium urate, ICC intraclass correlation coefficient values, 95% CI 95% confidence interval, $r$, Spearman rank correlation coefficient, NA not available.

*Spearmann correlation analysis between serum uric acid and the average volume of MSU crystals.
370 μmol/L, 572 μmol/L, and 464 μmol/L, respectively. As seen in Fig. 2a, four AxSpA patients were graded with a scale of 0, 0, II, III at the left sacroiliac joint and 0, I, II, III at the right sacroiliac joint, respectively, on plain radiographs. A large quantity of MSU crystal deposition was found at the sacroiliac joint or the surrounding area (Fig. 2b). The close relationship between MSU crystal deposition and radiographic structural damage (erosion, joint space narrowing, and new bone formation features) is shown at the sacroiliac joints of patients 2–4 (Fig. 2c-d).

Discussion

The umbrella of AxSpA encompasses both nr-AxSpA and classic AS by ASAS [1, 2]. However, the range of diagnoses for AxSpA may cause difficulty among a large population with back pain, especially with sacroiliitis in gout or crystal deposition diseases [28]. First, the publication of classification criteria for AxSpA has produced some false-positive and false-negative cases, due to the way that the aforementioned diseases may mimic AxSpA in clinical manifestations. Second, the coexistence of AxSpA with other rheumatic diseases is common. For example, with an increasing mean age of AS onset and a decreasing mean age of gout onset [29, 30] AS coexisting with gout is more common [9]. Finally, at a certain stage of disease duration in AxSpA patients without the gout history, the deposition of MSU crystal may only be transient, which is hard to detect with traditional radiology methods, but has a positive impact on disease progression.

Fortunately, the recently developed DECT imaging method has provided higher sensitivity and specificity for MSU crystal deposition in patients with symptomatic gout and asymptomatic hyperuricaemia [19]. Therefore, a DECT finding of MSU crystal deposition has been included in the 2015 American College of Rheumatology and the European League Against Rheumatism (ACR/EULAR) gout classification criteria [31]. Although a subclinical MSU crystal deposition by DECT is insufficient for a diagnosis of gout, those depositions are, in fact, widespread in the body of patients or even normal individuals. A previous study reported that 20% of hyperuricaemic RA patients show DECT MSU crystal depositions, which are significantly associated with seronegativity [32]. Moreover, MSU crystal deposition was also observed in multiple joints and soft tissues of the body in patients with asymptomatic hyperuricaemia and was associated with increasing severity of coronary calcification [19, 20]. Indeed, we have found a few cases of MSU crystal deposition depicted in green with DECT at painful joints or skeleton regions not only in patients with asymptomatic hyperuricaemia, but also in patients with iliac condensing ostitis, reactive arthritis, osteoarthritis, rheumatoid arthritis, and AxSpA in our clinical practice, when patients were considered for other causes of inflammatory activity. It may be meaningful that the MSU crystal deposited at those joints or skeleton regions. Those depositions may be involved in the process
of inflammation and bone destruction in primary diseases. In this study we reported that a large amount of MSU crystal deposition detected with DECT was in pelvic, hip joint, and sacroiliac joint regions in AxSpA patients without gout. Those findings indicated that it might be easy to ignore these regions in patients with AxSpA when it coexists with MSU crystal deposition, which may play an important role in the occurrence or development of the disease.

As is commonly known, hyperuricaemia and MSU crystal deposition are the central risk factors for development of gout. Three stages of MSU crystal deposition have been proposed: reduced urate solubility, MSU nucleation, and MSU crystal growth [33]. But there is no inevitable corresponding relationship between hyperuricaemia, MSU crystal deposition, and gout. For example, a recent study has shown that imaging evidence of MSU crystal deposition appears only in 24% of asymptomatic patients with AxSpA patients without gout. Those findings indicated that it might be easy to ignore these regions in patients with AxSpA when it coexists with MSU crystal deposition, which may play an important role in the occurrence or development of the disease.

As is commonly known, hyperuricaemia and MSU crystal deposition are the central risk factors for development of gout. Three stages of MSU crystal deposition have been proposed: reduced urate solubility, MSU nucleation, and MSU crystal growth [33]. But there is no inevitable corresponding relationship between hyperuricaemia, MSU crystal deposition, and gout. For example, a recent study has shown that imaging evidence of MSU crystal deposition appears only in 24% of asymptomatic patients with AxSpA patients without gout. Those findings indicated that it might be easy to ignore these regions in patients with AxSpA when it coexists with MSU crystal deposition, which may play an important role in the occurrence or development of the disease.

As is commonly known, hyperuricaemia and MSU crystal deposition are the central risk factors for development of gout. Three stages of MSU crystal deposition have been proposed: reduced urate solubility, MSU nucleation, and MSU crystal growth [33]. But there is no inevitable corresponding relationship between hyperuricaemia, MSU crystal deposition, and gout. For example, a recent study has shown that imaging evidence of MSU crystal deposition appears only in 24% of asymptomatic patients with AxSpA patients without gout. Those findings indicated that it might be easy to ignore these regions in patients with AxSpA when it coexists with MSU crystal deposition, which may play an important role in the occurrence or development of the disease.

As is commonly known, hyperuricaemia and MSU crystal deposition are the central risk factors for development of gout. Three stages of MSU crystal deposition have been proposed: reduced urate solubility, MSU nucleation, and MSU crystal growth [33]. But there is no inevitable corresponding relationship between hyperuricaemia, MSU crystal deposition, and gout. For example, a recent study has shown that imaging evidence of MSU crystal deposition appears only in 24% of asymptomatic patients with AxSpA patients without gout. Those findings indicated that it might be easy to ignore these regions in patients with AxSpA when it coexists with MSU crystal deposition, which may play an important role in the occurrence or development of the disease.

Table 3 Comparison of MSU crystal deposits at different regions and serum uric acid in patients grouped by ASDAS scores

| ASDAS scores       | MSU crystallization (+/-) (n) | Volume of MSU crystallization (cm³) | Serum uric acid (μmol/L) |
|--------------------|------------------------------|------------------------------------|--------------------------|
| ASDAS < 1.3 (n = 38) | 8/30                         | 0.21 ± 0.62                        | 321.0 ± 100.4            |
| 1.3 ≤ ASDAS < 2.1 (n = 38) | 6/32                         | 0.14 ± 0.47                        | 326.2 ± 104.2            |
| 2.1 ≤ ASDAS ≤ 3.5 (n = 50) | 16/34                        | 0.49 ± 1.34                        | 397.9 ± 109.4            |
| ASDAS > 3.5 (n = 60) | 27/33                        | 0.23 ± 0.57                        | 382.9 ± 99.8             |

Values are given as the numbers or the mean ± standard deviation (Mean±SD)

ASDAS Ankylosing Spondylitis Disease Activity Score, MSU monosodium urate

*Pearson chi-square (x²) test

Kruskal-Wallis rank-sum test

One-way analysis of variance (ANOVA)

of inflammation and bone destruction in primary diseases. In this study we reported that a large amount of MSU crystal deposition detected with DECT was in pelvic, hip joint, and sacroiliac joint regions in AxSpA patients without gout. Those findings indicated that it might be easy to ignore these regions in patients with AxSpA when it coexists with MSU crystal deposition, which may play an important role in the occurrence or development of the disease.

As is commonly known, hyperuricaemia and MSU crystal deposition are the central risk factors for development of gout. Three stages of MSU crystal deposition have been proposed: reduced urate solubility, MSU nucleation, and MSU crystal growth [33]. But there is no inevitable corresponding relationship between hyperuricaemia, MSU crystal deposition, and gout. For example, a recent study has shown that imaging evidence of MSU crystal deposition appears only in 24% of asymptomatic patients with AxSpA patients without gout. Those findings indicated that it might be easy to ignore these regions in patients with AxSpA when it coexists with MSU crystal deposition, which may play an important role in the occurrence or development of the disease.
interacting mechanisms between AxSpA and MSU crystal deposition, which ultimately results in damage to the sacroiliac joint. On the one hand, the structural damage mentioned above occurs through alteration of physiological bone turnover with excessive osteoclast activation, which was abnormally regulated by the receptor activator of nuclear factor-κB (RANK), RANK ligand (RANKL), and the osteoprotegerin (OPG) signaling pathway [37, 38]. Although new bone formation evolving into ankylosis is an important feature of AxSpA, the process of inflammation and subsequent bone erosion also occurs synchronously [39]. Meanwhile, bone erosion was also recognized at some interface of MSU crystal deposition, which erodes the bone and cartilage to cause significant structural damage [23]. On the other hand, a large amount of common inflammatory and proinflammatory factors have been involved in the promotion of bone damage, such as tumour necrosis factor alpha, interleukin (IL)-1, IL-6 [40, 41]. Accordingly, our observation that volumes of MSU crystal at the sacroiliac joints are associated with the progress of radiographic grade at sacroiliac joints is consistent with the current understanding of the pathogenesis, but the exact interacting mechanism needs further investigation.

| Characteristics | Based on the left sacroiliac joint damage | Based on the right sacroiliac joint damage |
|-----------------|------------------------------------------|------------------------------------------|
| Age, per year    | 1.016                                    | 1.025                                    |
| Male, vs female | 1.303                                    | 1.281                                    |
| AxSpA duration, per year | 1.189 | 1.195 |
| HLA-B27 positive, vs negative | 1.248 | 1.197 |
| ESR, per mm/h    | 1.024                                    | 1.032                                    |
| CRP, per mg/l    | 1.045                                    | 1.041                                    |
| Total back pain, per score | 1.298 | 1.263 |
| PGA of disease activity, per score | 1.214 | 1.221 |
| Pain and swelling of peripheral arthritis, per score | 1.849 | 1.950 |
| Duration of morning stiffness, per score | 1.242 | 1.234 |
| ASDAS, per score | 1.716                                    | 1.671                                    |
| BASFI, per score | 3.188                                    | 2.811                                    |
| Ever use of NSAIDs, vs never | 1.922 | 1.967 |
| Ever use of biologic DMARDs, vs never | 1.360 | 1.212 |
| ≤ 12 months     | 0.143                                    | 0.182                                    |
| ≤ 12 months     | 0.274                                    | 0.244                                    |
| ≤ 6 months      | 0.795                                    | 0.757                                    |
| Never           | NA                                       | NA                                       |
| Serum uric acid, per μmol/L | 1.001 | 1.001 |
| MSU crystallization positive, vs negative | 3.368 | 3.225 |
| Left sacroiliac joint | NA  | NA  |
| Right sacroiliac joint | 3.225 | 1.749 |
| Hip joint       | 0.715                                    | 0.674                                    |
| Pubic symphysis | 0.971                                    | 0.928                                    |
| Volume of MSU crystallization, per cm³ | 1.990 | 1.470 |
| Left sacroiliac joint | 1.990 | 1.147 |
| Right sacroiliac joint | 1.147 | 1.125 |
| Total volume at pelvis | 1.015 | 1.015 |

AxSpA axial spondyloarthritis, ESR erythrocyte sedimentation rate, CRP C-reactive protein, PGA patient’s global assessment, ASDAS Ankylosing Spondylitis Disease Activity Score, BASFI Bath Ankylosing Spondylitis Functional Index, NSAIDs non-steroidal anti-inflammatory drugs, DMARDs disease-modifying anti-rheumatic drugs, MSU monosodium urate, OR odds ratios, 95% CI 95% confidence interval, NA not available

*Including clinical variables and the DECT scans results"
Table 5: The ordinal logistic regression analysis of clinical features independently associated with the grade of sacroiliac joint damage

| Characteristics | Based on the left sacroiliac joint damage | Based on the right sacroiliac joint damage |
|-----------------|------------------------------------------|------------------------------------------|
|                 | Complex model 1                          | Simplified model 2                       | Complex model 3                          | Simplified model 4 |
|                 | AOR 95% CI p value                        | AOR 95% CI p value                        | AOR 95% CI p value                        | AOR 95% CI p value |
| AxSpA duration, per year | 1.187 1.089–1.294 0.000 | 1.180 1.086–1.283 0.000 | 1.090–1.295 0.000 | 1.190 1.096–1.293 0.000 |
| ESR, per mm/h    | 1.003 0.981–1.025 0.794 | 1.003 0.982–1.025 0.755 | 0.981–1.022 0.905 | 1.003 0.982–1.024 0.781 |
| CRP, per mg/l    | 1.038 0.999–1.079 0.058 | 1.018 0.991–1.046 0.019 | 0.987–1.065 0.196 | 1.008 0.981–1.036 0.576 |
| Total back pain, per score | 1.428 1.040–1.962 0.028 | 1.246 0.975–1.591 0.078 | 0.959–1.803 0.089 | 1.166 0.916–1.484 0.212 |
| PGA of disease activity, per score | 1.040 0.784–1.380 0.786 | 0.975 0.746–1.275 0.856 | 0.780–1.342 0.868 | 0.970 0.751–1.252 0.815 |
| Pain and swelling of peripheral arthritis, per score | 1.517 0.795–2.897 0.207 | 1.356 0.725–2.534 0.341 | 0.978–3.532 0.059 | 1.657 0.890–3.084 0.111 |
| Duration of morning stiffness, per score | 0.723 0.519–1.008 0.056 | 0.682 0.494–0.942 0.020 | 0.607–1.150 0.271 | 0.792 0.581–1.079 0.139 |
| ASDAS, per score | 0.492 0.179–1.354 0.170 | NA NA | 0.194–1.429 0.208 | NA NA |
| BASFI, per score | 3.837 2.263–6.506 0.000 | 3.800 2.250–6.417 0.000 | 3.092 1.896–5.044 0.000 | 3.034 1.870–4.922 0.000 |
| Ever use of biologic DMARDs, vs never | | | | |
| ≥ 12 months     | 1.051 0.308–3.581 0.937 | 1.144 0.337–3.885 0.829 | 1.425 0.417–4.872 0.572 | 1.870–4.754 0.575 |
| ≤ 12 months     | 0.961 0.333–2.778 0.942 | 1.098 0.385–3.132 0.861 | 0.971 0.329–2.866 0.958 | 1.020 0.357–2.916 0.891 |
| ≤ 6 months      | 1.999 0.806–4.962 0.135 | 1.830 0.745–4.495 0.188 | 2.461 0.976–6.204 0.056 | 2.128 0.869–5.211 0.099 |
| Never           | NA NA NA NA | NA NA | NA NA | NA NA |
| MSU crystallization positive, vs negative | | | | |
| Left sacroiliac joint | 0.895 0.391–2.049 0.794 | NA NA | NA NA | NA NA |
| Right sacroiliac joint | NA NA | NA NA | NA NA | NA NA |
| Volume of MSU crystallization, per cm³ | | | | |
| Left sacroiliac joint | 2.018 1.144–3.560 0.015 | 1.920 1.209–3.049 0.006 | NA NA | NA NA |
| Right sacroiliac joint | NA NA | NA NA | 1.387 1.022–1.882 0.036 | 1.418 1.075–1.870 0.014 |

Complex model 1 and 3, variables with p < 0.05 in bivariate analysis were included based on the radiographic grade at each sacroiliac joint; simplified model 2 and 4, the models with the repeated variables of the ASDAS score and MSU crystals deposits positive were excluded.

AxSpA: axial spondyloarthritis, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, PGA: patient's global assessment, ASDAS: Ankylosing Spondylitis Disease Activity Score, BASFI: Bath Ankylosing Spondylitis Functional Index, DMARDs: disease-modifying anti-rheumatic drugs, MSU: monosodium urate, AOR: adjusted odds ratio, 95% CI: 95% confidence interval, NA: not available.

*Including clinical variables and the DECT scans results.
There are several limitations of this study. First, the disease category for AxSpA includes classic AS and nr-AxSpA [1, 2]. A subgroup analysis has not been performed, due to the limited sample size. Second, structural damage grading at the sacroiliac joint was estimated by plain radiograph, according to the modified New York criteria [22]. The radiological scoring methods with CT [42, 43], which has higher density resolution and repeatability, should be applied in the structural damage assessment. Third, this study is a cross-sectional analysis. Further prospective studies would be valuable to confirm the precise contribution of MSU crystal deposition to the structural damage of the sacroiliac joints in patients with AxSpA.

Conclusions
In summary, the present study reveals that large quantities of MSU crystal deposition detected by DECT have been found in AxSpA patients without coexisting gout. In addition, it provides further evidence that the MSU crystal deposition at the sacroiliac joint in those patients has been associated with the progress of radiographic grade at sacroiliac joints, apart from AxSpA duration and BASFI score.

Abbreviations
ACR/EULAR: American College of Rheumatology and the European League Against Rheumatism; AS: ankylosing spondylitis; ASAS: Assessment of SpondyloArthritis International Society; ASDAS: Ankylosing Spondylitis Disease Activity Score; AxSpA: Axial spondyloarthritis; BASFI: Bath Ankylosing Spondylitis Functional Index; CRP: C-reactive protein; DECT: Dual-energy computed tomography; DMARDs: Disease-modifying anti-rheumatic drugs; ESR: Erythrocyte sedimentation rate; MRI: Magnetic resonance imaging; MSU: Monosodium urate; NSAIDs: Non-steroidal anti-inflammatory drugs; PGA: Patient’s global assessment; SpA: Spondyloarthritis; VAS: visual analogue scale

Acknowledgements
Not applicable.
Funding
This work was supported by the President Foundation of Nanfang Hospital, Southern Medical University (No. 2016CO24) and the Natural Science Foundation of China (No. 81573730). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
Not applicable: no supplementary files, no databases.

Authors’ contributions
IZ designed the study, performed the statistical analyses, drafted the manuscript, and revised the manuscript. AL participated in the design of the study, helped to carry out the statistical analyses and revised the manuscript. YZ participated in the statistical analyses, finished the compiling of tables and volumes of MSU crystal. JL conceived of the study, participated in the clinical variables and carry out the statistical analyses. YH helped to collect the clinical variables and produce the graphs. EJ and XX performed the plain radiographic scores as well as the DECT scan assessment for the presence and volumes of MSU crystal. JX collected of the study, participated in the design, helped to draft the manuscript, and was accountable for all aspects of the work. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was conducted according to the principles expressed in the Declaration of Helsinki. The study was approved by the Institutional Medical Ethics Review Board of Nanfang Hospital. All patients submitted the consent forms.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Rheumatology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China. 2Department of Internal Medicine of Traditional Chinese Medicine, College of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong 510510, China. 3Department of Obstetrics, Guangdong Women and Children Hospital, Guangzhou, Guangdong 511400, China. 4Department of Radiology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.

Received: 20 November 2016 Accepted: 24 March 2017
Published online: 02 May 2017

References
1. Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados M, Huang F, Gu J, Khan MA, Kirazli Y, Maksymowycz WP, Mielants H, Sorensen II, Ozgocmen S, Roussou E, Valle-Orante R, Weber U, Wei J, Sieper J. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–83.
2. Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J, Burgos-Vargas R, Collantes-Estevez E, Davis J, Dijkmans B, Dougados M, Emery P, van der Horst-Bruinse MA, Inman R, Khan MA, Leirisalo-Repo M, van der Linden S, Maksymowycz WP, Mielants H, Olivieri I, Sturrock R, de Vlam K, Sieper J. The development of the Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of patient papers by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009;68:770–6.
3. Bakland G, Nossent HC. Epidemiology of spondyloarthritis: A review. Curr Rheumatol Rep. 2013;15:351.
4. Evachou S, Lie E, Lindstrom U, Asling J, Forsblad-deElla H, Turesson C, Kristensen LE, Jacobsson LT. Mortality in ankylosing spondylitis: results from a nationwide population-based study. Ann Rheum Dis. 2016;75:1466–72.
5. Smith JA. Update on ankylosing spondylitis: current concepts in pathogenesis. Curr Allergy Asthma Rep. 2015;15:489.
6. Itulescu TC, Alexandrescu C, Voinea LM. Ocular involvement in spondylarthritids–new mechanisms, new therapies. Oftalmologia. 2014;58:27–35.
7. Kundur U, Cevik H, Demirdal US, Toktas H. Use of ruxolitinib to treat a patient with coexistence of rheumatoid arthritis and ankylosing spondylitis: 18 months follow-up. Int J Rheum Dis. 2014. doi:10.1111/1756-185X.12303.
8. Borman P, Aynan F, Okumus M. Coexistence of rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol. 2011;30:517–8.
9. Ho HH, Yu KH, Chen JY, Lin JI, Wu YJ, Luo SF, Liou LB. Coexisting ankylosing spondylitis and gouty arthritis. Clin Rheumatol. 2007;26:655–61.
10. Louropoulos A, Ioanipidis P, Boura E, Antoniadis D, Karacostas D, Grigoridiad N. Coexistence of multiple sclerosis and ankylosing spondylitis: report of two cases. Eur Neurol. 2013;70:149–54.
11. Borman P, Tuncay F, Koybasi M, Ergun U, Inan L. Coexistence of ankylosing spondylitis and multiple sclerosis. Acta Neurol Belg. 2011;111:340–3.
12. Singh S, Sonkar GK, Singh UJ. Coexistence of ankylosing spondylitis and systemic lupus erythematosus. J Chin Med Assoc. 2010;73:260–1.
13. Gran JT. An epidemiological survey of the signs and symptoms of ankylosing spondylitis. Clin Rheumatol. 1985;4:161–9.
14. Abraham Z, Gluck Z. Acute gout of the right sacroiliac joint. J Dermatol. 1997;24:781–3.
15. Kwan BY, Osman S, Barra L. Spinal gout in a young patient with involvement of thoracic, lumbar and sacroiliac regions. Joint Bone Spine. 2013;80:667–8.
16. Konatalapalli RM, Demarco PJ, Jelinek JS, Murphy M, Gibson M, Jennings B, Weinstein A. Gout in the axial skeleton. J Rheumatol. 2009;36:609–13.
17. Glazebrook KN, Guimaraes LS, Murthy NS, Black DF, Bongartz T, Manek NJ, Leng S, Fletcher JS, McCollough CH. Identification of intraarticular and perianular uric acid crystals with dual-energy CT: initial evaluation. Radiology. 2011;261:516–24.
18. Ogdie A, Taylor WJ, Weatherall M, Fransen J, Jansen TL, Neogi T, Schumacher HR, Dalbeth N. Imaging modalities for the classification of gout: systematic literature review and meta-analysis. Ann Rheum Dis. 2015;74:1968–74.
19. Dalbeth N, House ME, Aati O, Tan P, Franklin C, Horne A, Gambling GD, Stamp LK, Doyle AJ, McQueen FM. Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study. Ann Rheum Dis. 2015;74:900–11.
20. Andres M, Quintanilla MA, Sivera F, Sanchez-Paya J, Pascual E, Vela P, Ruiz-Nodar JM. Silent monosodium urate crystals deposits associate with severe coronary calcification in asymptomatic hyperuricaemia: “an exploratory study”. Arthritis Rheumatol. 2016;68:1531–9.
21. Wallace SL, Robinson H, Massi AT, Deckler JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritids of primary gout. Arthritis Rheum. 1997;40:895–900.
22. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361–8.
23. Dalbeth N, Aati O, Kalluru R, Gambling GD, Horne A, Doyle AJ, McQueen FM. Relationship between structural joint damage and uate deposition in gout: a plain radiography and dual-energy CT study. Ann Rheum Dis. 2015;74:1030–6.
24. van der Heijde D, Lie E, Kven TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewe R. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:1811–8.
25. Macchado P, Landewe R, Lie E, Kven TK, Braun J, Baker D, van der Heijde D. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70:474–33.
26. Calm A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Malloie P, Jenkinson T. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol. 1994;21:2281–5.
27. Rajan A, Aati O, Kalluru R, Gambling GD, Horne A, Doyle AJ, McQueen FM, Dalbeth N. Lack of change in uate deposition by dual-energy computed tomography among clinically stable patients with long-standing
tophaceous gout: a prospective longitudinal study. Arthritis Res Ther. 2013;15:R160.

28. Braun J, Baraliakos X, Kiltz U, Heldmann F, Sieper J. Classification and diagnosis of axial spondyloarthritis—what is the clinically relevant difference? J Rheumatol. 2015;42:311–8.

29. Yu KH, Luo SF. Younger age of onset of gout in Taiwan. Rheumatology (Oxford). 2003;42:166–70.

30. Will R, Calin A, Kirwan J. Increasing age at presentation for patients with ankylosing spondylitis. Ann Rheum Dis. 1992;51:340–2.

31. Neogi T, Jansen TLTA, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJEM, Lióte F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sunde J, Tausche A, Vaquez-Mellado J, Yarows SA, Taylor WJ. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74:1789–98.

32. Petsch C, Araujo EG, Englbrecht M, Bayat S, Cavallaro A, Hueber AJ, Lell M, Schett G, Manger B, Rech J. Prevalence of monosodium urate deposits in a population of rheumatoid arthritis patients with hyperuricemia. Semin Arthritis Rheum. 2016;45:663–8.

33. Chhana A, Lee G, Dalbeth N. Factors influencing the crystallization of monosodium urate: a systematic literature review. BMC Musculoskeletal Disord. 2015;16:296.

34. Dougados M, Demattei C, van den Berg R, Hoang W, Thevenin F, Reijnierse M, Loeuille D, Feydy A, Claudepierre P, van der Heijde D. Rate and predisposing factors of sacroiliac radiographic progression after a 2 years follow-up period in recent onset spondyloarthritis. Arthritis Rheumatol. 2016;68:1904–13.

35. Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70:1369–74.

36. Blachier M, Canoui-Poitrine F, Dougados M, Lethuaut A, Fautrel B, Fenkal S, Le Corvoisier P, Farrenq V, Pouliquen C, Ghaleh B, Bastuji-Garin S, Claudepierre P. Factors associated with radiographic lesions in early axial spondyloarthritis. Results from the DESIR cohort. Rheumatology (Oxford). 2013;52:1686–93.

37. Chhana A, Gallon KE, Pool B, Naot D, Watson M, Gamble GD, McQueen FM, Cornish J, Dalbeth N. Monosodium urate monohydrate crystals inhibit osteoblast viability and function: implications for development of bone erosion in gout. Ann Rheum Dis. 2011;70:1684–91.

38. Puri RL, Scano A, Ramonda R, Oliviero F. Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets. Autoimmun Rev. 2012;12:66–71.

39. Hreggvidsdottir HS, Noordenbos T, Baeten DL. Inflammatory pathways in ankylosing spondylitis. Mol Immunol. 2014;57:28–37.

40. Qoqocmen S, Ardicioğlu O, Kaya A. The relationship of clinical and laboratory measurements to two different radiological scoring methods in ankylosing spondylitis. J Back Musculoskelet Rehabil. 2000;13:37–40.

41. Taylor HG, Wardle T, Beswick EJ, Dawes PT. The relationships of clinical and laboratory measurements to radiological change in ankylosing spondylitis. Br J Rheumatol. 1991;30:330–5.